« Return to News | Drug Sponsors

GSK seeks $2 billion acquisition in India

Thursday, October 6, 2011 11:58 AM

GlaxoSmithKline is eyeing acquisitions worth as much as $2 billion in India in an effort to cement its position in one of the world's fastest-growing drug markets, the group's chief executive told U.K. newspaper The Times in an interview, according to Dow Jones Newswires.

In a wide-ranging interview during a visit to Mumbai, Andrew Witty said that GSK was seeking "bolt-on acquisitions" in Asia's third-biggest economy to strengthen its emerging markets business, which he has made a key strategic focus since taking over as chief executive in 2008, The Times said.

"India is clearly on the radar," he said, adding that he expected the company to spend between $500 million and $2 billion, according to The Times. "I would love to buy something in India." Mr. Witty cautioned that GSK, which employs 5,000 people and turns over more than $1 billion in the country, was unlikely to pursue larger-scale mergers and acquisitions and was unwilling to overpay for companies.

"We already have an enviable brand in India so there is no need for us to pay a strategic premium," he said. "Others might need to do that, but we don't."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.